Literature DB >> 25636762

Nanoparticle-based brachytherapy spacers for delivery of localized combined chemoradiation therapy.

Rajiv Kumar1, Jodi Belz2, Stacey Markovic3, Tej Jadhav2, William Fowle2, Mark Niedre3, Robert Cormack4, Mike G Makrigiorgos4, Srinivas Sridhar5.   

Abstract

PURPOSE: In radiation therapy (RT), brachytherapy-inert source spacers are commonly used in clinical practice to achieve high spatial accuracy. These implanted devices are critical technical components of precise radiation delivery but provide no direct therapeutic benefits. METHODS AND MATERIALS: Here we have fabricated implantable nanoplatforms or chemoradiation therapy (INCeRT) spacers loaded with silica nanoparticles (SNPs) conjugated containing a drug, to act as a slow-release drug depot for simultaneous localized chemoradiation therapy. The spacers are made of poly(lactic-co-glycolic) acid (PLGA) as matrix and are physically identical in size to the commercially available brachytherapy spacers (5 mm × 0.8 mm). The silica nanoparticles, 250 nm in diameter, were conjugated with near infrared fluorophore Cy7.5 as a model drug, and the INCeRT spacers were characterized in terms of size, morphology, and composition using different instrumentation techniques. The spacers were further doped with an anticancer drug, docetaxel. We evaluated the in vivo stability, biocompatibility, and biodegradation of these spacers in live mouse tissues.
RESULTS: The electron microscopy studies showed that nanoparticles were distributed throughout the spacers. These INCeRT spacers remained stable and can be tracked by the use of optical fluorescence. In vivo optical imaging studies showed a slow diffusion of nanoparticles from the spacer to the adjacent tissue in contrast to the control Cy7.5-PLGA spacer, which showed rapid disintegration in a few days with a burst release of Cy7.5. The docetaxel spacers showed suppression of tumor growth in contrast to control mice over 16 days.
CONCLUSIONS: The imaging with the Cy7.5 spacer and therapeutic efficacy with docetaxel spacers supports the hypothesis that INCeRT spacers can be used for delivering the drugs in a slow, sustained manner in conjunction with brachytherapy, in contrast to the rapid clearance of the drugs when administered systemically. The results demonstrate that these spacers with tailored release profiles have potential in improving the combined therapeutic efficacy of chemoradiation therapy.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25636762      PMCID: PMC4527168          DOI: 10.1016/j.ijrobp.2014.10.041

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  31 in total

1.  Permanent prostate brachytherapy: the significance of postimplant dosimetry.

Authors:  W Robert Lee
Journal:  Rev Urol       Date:  2004

2.  Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09.

Authors:  Anthony L Zietman; Kyounghwa Bae; Jerry D Slater; William U Shipley; Jason A Efstathiou; John J Coen; David A Bush; Margie Lunt; Daphna Y Spiegel; Rafi Skowronski; B Rodney Jabola; Carl J Rossi
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

3.  Organically modified silica nanoparticles with covalently incorporated photosensitizer for photodynamic therapy of cancer.

Authors:  Tymish Y Ohulchanskyy; Indrajit Roy; Lalit N Goswami; Yihui Chen; Earl J Bergey; Ravindra K Pandey; Allan R Oseroff; Paras N Prasad
Journal:  Nano Lett       Date:  2007-08-25       Impact factor: 11.189

4.  Prostate cancer in elderly men.

Authors:  Anton Stangelberger; Matthias Waldert; Bob Djavan
Journal:  Rev Urol       Date:  2008

Review 5.  Nanoparticles in cancer therapy and diagnosis.

Authors:  Irène Brigger; Catherine Dubernet; Patrick Couvreur
Journal:  Adv Drug Deliv Rev       Date:  2002-09-13       Impact factor: 15.470

6.  Taxol sensitizes human astrocytoma cells to radiation.

Authors:  R B Tishler; C R Geard; E J Hall; P B Schiff
Journal:  Cancer Res       Date:  1992-06-15       Impact factor: 12.701

7.  PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral.

Authors:  J L Italia; D K Bhatt; V Bhardwaj; K Tikoo; M N V Ravi Kumar
Journal:  J Control Release       Date:  2007-02-14       Impact factor: 9.776

Review 8.  Targeting multidrug resistance in cancer.

Authors:  Gergely Szakács; Jill K Paterson; Joseph A Ludwig; Catherine Booth-Genthe; Michael M Gottesman
Journal:  Nat Rev Drug Discov       Date:  2006-03       Impact factor: 84.694

Review 9.  Nanocarriers as an emerging platform for cancer therapy.

Authors:  Dan Peer; Jeffrey M Karp; Seungpyo Hong; Omid C Farokhzad; Rimona Margalit; Robert Langer
Journal:  Nat Nanotechnol       Date:  2007-12       Impact factor: 39.213

10.  Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo.

Authors:  G Mittal; D K Sahana; V Bhardwaj; M N V Ravi Kumar
Journal:  J Control Release       Date:  2007-02-03       Impact factor: 9.776

View more
  14 in total

1.  A Monte Carlo study of I-125 prostate brachytherapy with gold nanoparticles: dose enhancement with simultaneous rectal dose sparing via radiation shielding.

Authors:  D Brivio; P L Nguyen; E Sajo; W Ngwa; P Zygmanski
Journal:  Phys Med Biol       Date:  2017-01-31       Impact factor: 3.609

2.  Modeling gold nanoparticle-eluting spacer degradation during brachytherapy application with in situ dose painting.

Authors:  Francis Boateng; Wilfred Ngwa
Journal:  Br J Radiol       Date:  2017-05-04       Impact factor: 3.039

Review 3.  Theragnostic potentials of core/shell mesoporous silica nanostructures.

Authors:  Aswathy Ravindran Girija; Sivakumar Balasubramanian
Journal:  Nanotheranostics       Date:  2019-01-01

Review 4.  Using immunotherapy to boost the abscopal effect.

Authors:  Wilfred Ngwa; Omoruyi Credit Irabor; Jonathan D Schoenfeld; Jürgen Hesser; Sandra Demaria; Silvia C Formenti
Journal:  Nat Rev Cancer       Date:  2018-02-16       Impact factor: 60.716

Review 5.  Smart Radiation Therapy Biomaterials.

Authors:  Wilfred Ngwa; Francis Boateng; Rajiv Kumar; Darrell J Irvine; Silvia Formenti; Twalib Ngoma; Carsten Herskind; Marlon R Veldwijk; Georg Lars Hildenbrand; Michael Hausmann; Frederik Wenz; Juergen Hesser
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-11-01       Impact factor: 7.038

6.  Novel bioerodable eluting-spacers for radiotherapy applications with in situ dose painting.

Authors:  Francis Boateng; Wilfred Ngwa
Journal:  Br J Radiol       Date:  2019-05-14       Impact factor: 3.039

7.  Docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model.

Authors:  Céline Mirjolet; Julien Boudon; Alexis Loiseau; Sandy Chevrier; Romain Boidot; Alexandra Oudot; Bertrand Collin; Etienne Martin; Pattayil Alias Joy; Nadine Millot; Gilles Créhange
Journal:  Int J Nanomedicine       Date:  2017-08-30

8.  Light-Responsive Micelles Loaded With Doxorubicin for Osteosarcoma Suppression.

Authors:  Jiayi Chen; Chenhong Qian; Peng Ren; Han Yu; Xiangjia Kong; Chenglong Huang; Huanhuan Luo; Gang Chen
Journal:  Front Pharmacol       Date:  2021-06-18       Impact factor: 5.810

9.  Near-infrared fluorescence imaging platform for quantifying in vivo nanoparticle diffusion from drug loaded implants.

Authors:  Stacey Markovic; Jodi Belz; Rajiv Kumar; Robert A Cormack; Srinivas Sridhar; Mark Niedre
Journal:  Int J Nanomedicine       Date:  2016-03-24

10.  Sustained Release Talazoparib Implants for Localized Treatment of BRCA1-deficient Breast Cancer.

Authors:  Jodi E Belz; Rajiv Kumar; Paige Baldwin; Noelle Castilla Ojo; Ana S Leal; Darlene B Royce; Di Zhang; Anne L van de Ven; Karen T Liby; Srinivas Sridhar
Journal:  Theranostics       Date:  2017-09-26       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.